本报道最初发表于Endpoints News。请点击这里查看原文
The oncology field is buzzing after a landmark readout from Revolution Medicines, known colloquially as RevMed, showed that a targeted “pan-RAS” drug doubled the survival time for patients whose pancreatic cancer has returned or stopped responding to previous treatment. As cancer researchers and drugmakers head to San Diego this weekend for the annual AACR meeting, here’s what we’re watching:
在Revolution Medicines（革命医药，俗称“RevMed”）公布一项具有里程碑意义的结果后，肿瘤学领域一片沸腾：该结果显示，其一款靶向“pan‑RAS”的药物将复发或对既往治疗产生耐药的胰腺癌患者的生存时间提高了一倍。随着癌症研究人员和制药公司本周末奔赴圣地亚哥参加一年一度的美国癌症研究协会(AACR)年会，以下是我们关注的要点：
您已阅读15%（601字），剩余85%（3333字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。